Ceftriaxone
Amyotrophic Lateral Sclerosis
Massachusetts General HospitalSmall moleculePhase 3Dormant
B
56/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 48/ 100
- Competitive Position
- 73/ 100
Competitive context
148 Active assets in the Amyotrophic Lateral Sclerosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Taurursodiol Amylyx Pharmaceuticals Inc. | Phase 3 | BBB |
Tofersen Biogen | Phase 4 | BBB |
Riluzole AB Science | Phase 4 | BB |
Mexiletine Bjorn Oskarsson, MD | Phase 4 | BB |
Diacetyl(N(4)-Methylthiosemicarbazonato) Copper (Ii) Collaborative Medicinal Development Pty Limited | Phase 2/3 | BB |
View all 50 →
Same molecule, other indications
Ceftriaxone is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →